Zentalis Pharmaceuticals, Inc. Common Stock ZNTL
$2.60
-3.70%
at last close
Market Cap$255.61 million
P/E Ratio—
Div Yield—
Volume1.27M
52-Week Range
$1.21$6.95
Analyst Ratings
- Consensus
- Buy — 4 Buy · 1 Hold · 0 Sell (5 analysts)
- Avg. Price Target
- $8.25 (+217.3% upside)
Key Stats
- Today's Range
- $2.57 – $2.70
- 50-Day Range
- $2.57 – $5.58
- 52-Week Range
- $1.21 – $6.95
- Volume
- 1.27 million shs
- Average Volume
- 1.01 million shs
- Market Cap
- $255.61 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 1.78
- Price / Sales
- —
Short Interest
- Short Interest
- 0.64%
- Days to Cover
- 1.49
Financials (TTM)
- Revenue
- —
- Net Income
- $-139,545,000
- Net Margin
- —
- Return on Equity
- -97.15%
- Debt-to-Equity
- —
About Zentalis Pharmaceuticals, Inc. Common Stock
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
Related Stocks
Compare head-to-head: ZNTL vs LLY·ZNTL vs JNJ·ZNTL vs ABBV·ZNTL vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.